Arcturus Corp (ARCT) Enterprise Value to EBITDA Ratio

Public company logo of arcturusrx.com (ARCT)

The transition to the commercialization of the mRNA platform via licensing payments reduces unit costs, as reflected in the EV/EBITDA ratio of Arcturus Therapeutics (ARCT) on the financial timeline. The value of 0.00 determines the magnitude of this metric. Patent protection for nanoparticles and the high cost of trials limit the entry of new players, while a unique delivery system provides Arcturus Therapeutics (ARCT) with a competitive edge in the fierce race for biopharmaceutical leadership.

Arcturus Therapeutics Inc - ARCT Company Value to EBITDA (period 11/23/2025 - 11/12/2026)

Comprehensive metric breakdowns and analytics for arcturusrx.com (ARCT)

- current price and projected stock value:
Stock Price Arcturus Pharma|ARCT - Analyst Median Target
- market capitalization details:
Market Valuation Arcturus Corp|ARCT - Full Business Value
- business book valuation details:
Book Value per Share Arcturus Therapeutics|ARCT - Total Stockholders' Equity|Market Capitalization to Book Value Ratio arcturusrx.com|ARCT - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Arcturus Therapeutics|ARCT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Arcturus Therapeutics Holdings Inc.|ARCT - Company Aggregate Indebtedness|Debts to Book Capitalization Arcturus Corp|ARCT - Company Long-Term Loans and Borrowings|Company Short-Term Debts Arcturus Therapeutics|Quick Liquidity arcturusrx.com
- financial results and valuation multiples details:
ARCT - Final Profit|Expected Profit Arcturus Therapeutics|ARCT - Price to Earnings Ratio|Forward P/E Multiple Arcturus Therapeutics|ARCT - PEG Multiple|EV/EBITDA Multiple Arcturus Corp|ARCT - Operating profit EBITDA|Earnings per share for the last twelve months Arcturus Therapeutics|ARCT - Earnings per share for the trailing year|Quarterly EPS earnings growth arcturusrx.com|ARCT - Net earnings per share growth this year|Expected earnings per share growth for next year Arcturus Therapeutics
Fundamental valuation:Arcturus Pharma ARCT
Manufactured products of Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics (ARCT) is developing a high-tech portfolio of mRNA drugs through strategic alliances, which requires significant capital expenditures in infrastructure. The company's EV/EBITDA ratio compares the total enterprise value, including net debt, with its operating profit before depreciation and amortization, allowing investors to determine a fair acquisition price and assess the premium paid for control over innovative production.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma (BBIO)|BGM (BGM Group Limited) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Corp)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma)|KROS (kerostx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eton Pharmaceuticals, Inc. ETON|KMDA (Kamada Ltd) - Company Value to Operating Income Before Depreciation Ratio|Fulcrum Tx - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation ABEO (Abeona Therapeutics)|MREO: EV/EBITDA Multiple|protalix.com (PLX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pliant Therapeutics Inc|APLT: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rein Therapeutics, Inc. (RNTX)|Enterprise Value to EBITDA Ratio gelteq.com GELS|EV/EBITDA Multiple AYTU (Aytu BioPharma)|EV/EBITDA Multiple Chemomab Therapeutics Ltd CMMB|SRx Health - EV/EBITDA Multiple|PLRZ - EV/EBITDA Multiple|zentaris.com (AEZS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Cyclo Therapeutics, Inc - Business Value to Operating Income Before Depreciation|INZY (Inozyme Pharma Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio reneopharma.com (RPHM)|Enterprise Value to EBITDA Ratio CSCI (COSCIENS Biopharma)